[{"address1": "701 Veterans Circle", "city": "Warminster", "state": "PA", "zip": "18974", "country": "United States", "phone": "267 469 0914", "website": "https://www.arbutusbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael J. McElhaugh", "age": 49, "title": "Co-Founder, Interim President, CEO & Director", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 644400, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael J. Sofia Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 656100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David C. Hastings CPA", "age": 62, "title": "CFO & Chief Accounting Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 647100, "exercisedValue": 0, "unexercisedValue": 24750}, {"maxAge": 1, "name": "Ms. Lisa M. Caperelli", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. J. Christopher Naftzger BA, Esq., J.D.", "age": 56, "title": "General Counsel, Chief Compliance Officer & Secretary", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shannon  Briscoe SPHR", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Karen  Sims M.D., Ph.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.", "age": 72, "title": "Corporate Secretary", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.09, "open": 4.17, "dayLow": 4.17, "dayHigh": 4.52, "regularMarketPreviousClose": 4.09, "regularMarketOpen": 4.17, "regularMarketDayLow": 4.17, "regularMarketDayHigh": 4.52, "beta": 1.91, "forwardPE": -12.8857155, "volume": 3249135, "regularMarketVolume": 3249135, "averageVolume": 995632, "averageVolume10days": 1106150, "averageDailyVolume10Day": 1106150, "bid": 4.47, "ask": 4.52, "bidSize": 100, "askSize": 600, "marketCap": 851406848, "fiftyTwoWeekLow": 1.69, "fiftyTwoWeekHigh": 4.52, "priceToSalesTrailing12Months": 84.62447, "fiftyDayAverage": 3.641, "twoHundredDayAverage": 2.89845, "currency": "USD", "enterpriseValue": 637588480, "floatShares": 135509628, "sharesOutstanding": 188782000, "sharesShort": 6644653, "sharesShortPriorMonth": 7019110, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0352, "heldPercentInsiders": 0.22304001, "heldPercentInstitutions": 0.51423, "shortRatio": 7.49, "shortPercentOfFloat": 0.044699997, "impliedSharesOutstanding": 188782000, "bookValue": 0.649, "priceToBook": 6.949153, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -77087000, "trailingEps": -0.45, "forwardEps": -0.35, "lastSplitFactor": "1:5", "lastSplitDate": 1288828800, "enterpriseToRevenue": 63.372, "enterpriseToEbitda": -7.873, "52WeekChange": 0.96634614, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ABUS", "underlyingSymbol": "ABUS", "shortName": "Arbutus Biopharma Corporation", "longName": "Arbutus Biopharma Corporation", "firstTradeDateEpochUtc": 1185456600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "327b69f1-b9aa-3465-8efa-89ecddd8ae31", "messageBoardId": "finmb_34160168", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.51, "targetHighPrice": 5.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.6, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 141986000, "totalCashPerShare": 0.752, "ebitda": -80989000, "totalDebt": 7456000, "quickRatio": 6.375, "currentRatio": 6.56, "totalRevenue": 10061000, "debtToEquity": 6.089, "revenuePerShare": 0.058, "returnOnAssets": -0.30586, "returnOnEquity": -0.59956, "freeCashflow": -42819500, "operatingCashflow": -72875000, "revenueGrowth": -0.629, "operatingMargins": -12.38239, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]